PIN1 and hepatocellular carcinoma: found that the inhibitor API-1 interacts with peptidyl-prolyl cis-trans isomerase NIMA by targeting 1 (Pin1) to regulate miRNA biogenesis and inhibit HCC development, which could be a candidate for HCC treatment (144).